Porton J-STAR
30+Years
12000m2Area
60%Doctor Degree
Facilities
New Jersey 1-South Plainfield R&D Site
- 34 Fume Hoods in Seven Laboratories
- 2 GMP Kilo Labs with ChemGlass Reactors – up to 100L
- 2 Analytical Suites for On-Site Method Development and Release Testing
- Hydrogenation Room – up to 20L Capacity at 1500 psi
- 2 High Field NMRs On-Site (400 MHz and 300 MHz)
- Multiple HPLC + GC + LC/MS Instruments for Routine Walk-Up Access
- Catalysis & Enabling Technology Hub
- Scheduled Compound (II-IV) Handling
New Jersey 2-Cranbury R&D Site
- 34 Fume Hoods in multiple laboratories
- 4 Walk in Kilo lab Walk-in Hoods with up to 100 L Vessel Processing
- 1 High Potency Compound Handling Suite with 2 Isolators: cGMP Compliant in 2018
- 1 Analytical Suite for On-Site Method Development and Release Testing
- 1 Quality Control Suite for Release Testing
- 2 High Field NMRs on Site (500 MHz with Cryo probe and 400 MHz)
- Multiple HPLC + GC + LC/MS Instruments for Routine Walk-Up Access
- Crystallization R&D
- Preformulation and Formulation
- High Resolution Orbitrap UPLC-MS
- Structural Elucidation Hub
Services
Drug Substance
Porton offers efficient, flexible, and high-quality solutions for custom development and production of small molecule APIs, as well as technical services throughout the entire lifecycle from pre-clinical to commercial to our worldwide partners.
- Route Scouting/Design, Early and Late Phase process R&D; GMP Delivery
- Impurity Isolation Synthesis
- HPAPI, ADC Linker and Payload
- Catalysis & Flow Chemistry Technologies
High Potent API & Potent Compounds
Optimized HPAPIs, ADCs and potent compounds development and manufacturing (non-GMP and cGMP) tailored to your specific needs in our new 3000 sq facility equipped with Glovebox Workstations (Isolators) capable of less than 30 ng/m containment.
1)GMP Facilities:
- OEB 5 (<1 μg/m³)
- Bench & Walk-In Hoods
- Up to 100 L Vessels
- Prep HPLC and Lyophilizer
- Mobile Gloveboxes
- Flexible Single-Use-Systems for Powder Handling
2)non-GMP Facilities:
- OEB 5 (<1 μg/m³)
- Extract-Walker Barrier Isolators: 2
- HPAPI Linear Glove Box Feet: 2*8
Drug Product R&D and GMP Manufacturing
At our state-of-art R&D laboratory and expansive 5,100 sq ft GMP facility, we provide tailored drug product development services designed to fast-track the advancement of your Phase I and II drug products.
- Comprehensive Formulation Development
- Clinical Trial Material Manufacturing
- Enabling Formulation Technologies
- Solubility Enhancement and Bioavailability Optimization
- DS-DP Co-processing
Crystallization & Material Science
We offer fast, effective, phase appropriate and first-time right solutions which are based on scientific understanding to challenges in solid form and crystallization process by utilizing our technical expertise and extensive experience in the industry.
- Crystallization Process Development
- Particle Engineering
- Solid Form Screen/Selection/Studies
- Pre-formulation Evaluation
Analytical R&D and QC
We provide Analytical development and QC expertise at all stages of DS and DP development. With tailored workflows, advanced instrumentation, and a team of expert scientists, we deliver actionable insights that enhance product quality, reduce development timelines, and ensure regulatory compliance.
- Analytical Development and QC
- Method Validation
- Stability Study
- Structural Elucidation
One Porton One Quality
Compliance standards, Continuous improvement, Customer oriented
News
MoreNews2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
More
News2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
More
News2024-10-14
Driving innovation and excellence in the CDMO industry, Porton Pharma Solutions 2024 CPHI Europe Review
More
News2024-10-10
Connect with Porton J-STAR at AAPS PharmSci 360 2024 @ Booth 2431
More
News2024-09-30
Technical Enability | Porton’s Team of Global Chemical Engineering and Technology Published Breakthrough Results in Crystal Growth & Design and reported them at the 2024 Crystal Engineering Gordon Research Conference
More